View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 13, 2017

iCAN and Aura Medical to offer nebulisers for medical cannabis

iCAN:Israel-Cannabis has partnered with respiratory devices maker Aura Medical to offer the US Food and Drug Administration (FDA)-approved nebulisers for delivery of medical cannabis.

iCAN:Israel-Cannabis has partnered with respiratory devices maker Aura Medical to offer the US Food and Drug Administration (FDA) approved nebulisers for delivery of medical cannabis.

Aura’s Nebican Portable Nebuliser is developed for use as part of the treatment for asthma and chronic obstructive pulmonary disease (COPD).

The portable and easy-to-use device is designed using Vibrating Mesh Technology (VMT) and utilises specially formulated controlled dosages.

Nebican is said to use atomisation to deliver thin, fog-like mist that could easily penetrate into the lungs.

Aura Medical CEO Connie Lefkowitz said: “We are proud to pair our unique delivery platform, that, until now, has been used for prescription medications, including Albuterol, Pulmicort Respules, DuoNeb Intal and others, with targeted formulation from Ci Therapeutics.”

Ci Therapeutics, which was established as a joint venture between iCAN and CannRX, is a cannabis company that has been validating ican.sleep cannaceutical for delivery through Nebican.

“The firms intend to launch both Nebican and ican.sleep mid-next year in California, US, with plans to expand into Canada.”

The firms intend to launch both Nebican and ican.sleep mid-next year in California, US, with plans to expand into Canada.

iCAN:Israel-Cannabis founder and CEO Saul Kaye said: “This is a game changer, taking an advanced pulmonary FDA-approved delivery platform and formulating a sleep product to deliver safe cannabis in a doseable and repeatable way.”

Ci Therapeutics focuses on offering a platform for advanced, clinically validated formulations on pharmaceutical grade delivery systems.

CannRx develops quantitative and qualitative analytical chemical assays and disease-specific bioassays to identify specific cannabinoid activity in the cannabis plant.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU